Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516033 | 0.84 | TAAR1 (0.73) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL26615 | 0.84 | SLC6A2 (1.00) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL10392295 | 0.84 | SLC6A2 (1.00) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL3676484 | 0.82 | SLC6A2 (0.95) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL2477835 | 0.82 | SLC6A2 (0.70) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL28695767 | 0.82 | SLC6A2 (0.95) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL41585 | 0.82 | SLC6A2 (0.95) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL28729624 | 0.82 | SLC6A2 (0.95) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| SCHEMBL10503241 | 0.80 | TAAR1 (0.67) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 | |
| Phentermine SCHEMBL25214698 | 0.80 | SLC6A2 (0.91) | TAAR1SLC6A2CYP2D6LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017358-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4472995-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023150618-A2 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-3700922-A1 | VESICLE INCORPORATING TRANSMEMBRANE PROTEIN | Aquaporin A/S (DK) | 2020-09-02 | — | — | EP | disclosed |
| WO-2020162418-A1 | COLORLESS TRANSPARENT POLYIMIDE FILM | 三菱瓦斯化学株式会社 | 2020-08-13 | — | — | WO | disclosed |
| EP-3212183-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | University of Rochester (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016070021-A1 | SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS | UNIVERSITY OF ROCHESTER (US) | 2016-05-06 | — | — | WO | disclosed |
| CN-103172531-B | Diphenylamine compound, polyamic acid composition prepared from diphenyl amine compound, polyimide composition and liquid crystal alignment agent | DAXIN MATERIALS CORP. (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-104292184-A | Phenylenediamine compound, polymer, composition for alignment film, and liquid crystal display module | DAXIN MATERIALS CORP | 2015-01-21 | — | — | CN | disclosed |
| EP-0948496-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE | Amgen inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0929563-A1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | Abbott Laboratories (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1999015136-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-04-01 | — | — | WO | disclosed |
| EP-0876388-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1998030574-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998024780-A2 | SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE | AMGEN INC. (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1998009978-A1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997017356-A1 | TRICYCLIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-05-15 | — | — | WO | disclosed |
| US-4289885-A | 3-[2-(Dimethylamino)-2-phenylethyl]N-[phenylamino)carbonyl]sydnone imine, a new central nervous system stimulant | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | TAAR1 3031/4885SLC6A2 3658/4885CYP2D6 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.